Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

SONN - Sonnet BioTherapeutics Holdings, Inc.

IEX Last Trade
1.48
0   0%

Share volume: 707
Last Updated: Fri 27 Dec 2024 08:29:37 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 0.25%

PREVIOUS CLOSE
CHG
CHG%
$1.48
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
3.47%
1 Month
-43.35%
3 Months
109.98%
6 Months
56.84%
1 Year
-3.87%
2 Year
-93.49%
Key data
Stock price
$1.48
P/E Ratio 
0.00
DAY RANGE
$1.46 - $1.49
EPS 
$0.00
52 WEEK RANGE
$0.71 - $10.02
52 WEEK CHANGE
-$14.37
MARKET CAP 
3.751 M
YIELD 
N/A
SHARES OUTSTANDING 
5.203 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
1.09
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$253,316
AVERAGE 30 VOLUME 
$2,780,524
Company detail
CEO: Pankaj Mohan
Region: US
Website: sonnetbio.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Sonnet BioTherapeutics Holdings, Inc. develops platform for biologic medicines of single or bispecific action. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer.

Recent news